tbuckley/cabot-search huggingface dataset:
Abnormalities of follicular helper T-cell number and function in Wiskott-Aldrich syndrome
Authors: Xuan Zhang, Rongxin Dai, Wenyan Li, Hongyi Zhao, Yongjie Zhang, Lina Zhou, Hongqiang Du, Guangjin Luo, Junfeng Wu, Linlin Niu, Yunfei An, Zhiyong Zhang, Yuan Ding, Wenxia Song, Chaohong Liu, Xiaodong Zhao
Journal: Blood (2016)
Experimental Studies on Asbestos Carcinogenicity
Authors: L. M. Shabad, L. N. Pylev, L. V. Krivosheeva, T. F. Kulagina, B. A. Nemenko
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Experimental Studies on Asbestos Carcinogenicity Get access L. M. Shabad, L. M. Shabad Search for other works by this author on: Oxford Academic PubMed Google Scholar L. N. Pylev, L. N. Pylev Search for other works by this author on: Oxford Academic PubMed Google Scholar L. V. Krivosheeva, L. V. Krivosheeva Search for other works by this author on: Oxford Academic PubMed Google Scholar T. F. Kulagina, T. F. Kulagina Search for other works by this author on: Oxford Academic PubMed Google Scholar B. A. Nemenko B. A. Nemenko Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1175–1187, https://doi.org/10.1093/jnci/52.4.1175 Published: 01 April 1974 Article history Received: 22 August 1973 Accepted: 28 November 1973 Published: 01 April 1974
Use of Very Small Embryonic-Like Stem Cells to Avoid Legal, Ethical, and Safety Issues Associated With Oncofertility—Reply
Authors: Clarisa R. Gracia, Teresa Woodruff
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
HIV disease and other immunosuppressed patients
Authors: M. J. O’Doherty
Journal: Clinical Nuclear Medicine (1998)

The use of imaging in the immunosuppressed patient provides a new variety of causes for abnormalities of common scans. An awareness of the cause(s) is the prime need, and therefore, it is essential to be informed of the immune competence of an individual when reporting scans and to have a high level of suspicion.
Case 2-1968
Authors: J. Gordon Scannell, Benjamin Castleman
Journal: New England Journal of Medicine (1968)

Presentation of CaseA fifty-eight-year-old man was admitted to the hospital because of weakness, loss of weight and abdominal distention.He had been well until two years previously, when he entered another hospital because of fever and right anterior pleuritic pain. He also complained of frequent postprandial epigastric pain, which was relieved by antacids. X-ray films of the chest demonstrated a small right pleural effusion (Fig. 1). A thoracentesis was performed; the findings were unknown. He was told that he had had a pulmonary embolus, and warfarin therapy was begun. Seven months later the right pleuritic pain recurred, and x-ray . . .
Advance in bioequivalence assessment of topical dermatological products
Authors: Mei Lu, Haonan Xing, Xiao Chen, Lei Xian, Jingzheng Jiang, Tianzhi Yang, Pingtian Ding
Journal: Asian Journal of Pharmaceutical Sciences (2016)

Bioequivalence (BE) assessment of topical dermatological products is a long standing challenge. The development of generic topical dermatological products has often been hampered due to the limited number of acceptable approaches, which are capable of determining the BE between generic products and reference list products. The aim of this manuscript is to review different BE assessment approaches of topical dermatological products. Besides, the advances in BE evaluation and biowaivers are also provided. Currently, except in the case of dermatological corticosteroids, the golden rule to establish the BE of most topical dermatological products still heavily relied on clinical endpoint trials, which are often unreliable, time-consuming and expensive. The regulatory agencies and pharmaceutical industries are forging ahead to the development of new surrogate BE assessment approaches for other topical dermatological products. These promising approaches include dermatopharmacokinetic study (DPK), dermal microdialysis (DMD), in vitro studies, pharmacokinetic study (PK), near-infrared spectrometry (NIR), and confocal Raman spectroscopy (CRS). In addition, the expansion of biowaivers for topical dermatological products has been explored by pharmaceutical scientists. In conclusion, to accelerate the development and approval of topical dermatological products, emphasis should be put on the following areas, i.e., optimizing and standardizing the existing BE assessment methods, exploring novel alternatives of BE assessment approaches, and expanding biowaivers for topical dermatological products.
An Electron Microscopic Study of Virus Particles in Spontaneous Leukemia in the Cat&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Laird, Helen M., Jarrett, Oswald, Crighton, G. W., Jarrett, W. F. H.
Journal: JNCI Journal of the National Cancer Institute (1968)

Journal Article An Electron Microscopic Study of Virus Particles in Spontaneous Leukemia in the Cat Get access Helen M. Laird, Helen M. Laird Animal Leukaemia Research Unit, University of Glasgow, Glasgow, Scotland Search for other works by this author on: Oxford Academic PubMed Google Scholar Oswald Jarrett, Oswald Jarrett Animal Leukaemia Research Unit, University of Glasgow, Glasgow, Scotland Search for other works by this author on: Oxford Academic PubMed Google Scholar G. W. Crighton, G. W. Crighton Animal Leukaemia Research Unit, University of Glasgow, Glasgow, Scotland Search for other works by this author on: Oxford Academic PubMed Google Scholar W. F. H. Jarrett W. F. H. Jarrett Animal Leukaemia Research Unit, University of Glasgow, Glasgow, Scotland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 41, Issue 4, October 1968, Pages 867–878, https://doi.org/10.1093/jnci/41.4.867 Published: 01 October 1968 Article history Received: 28 March 1968 Accepted: 03 July 1968 Published: 01 October 1968
Counterpoint: The Case<i>Against</i>Adjuvant High-Dose Interferon-α for Melanoma Patients
Authors: Paul B. Chapman
Journal: Journal of the National Comprehensive Cancer Network (2004)

High dose interferon-α (HD IFN) is approved by the United States Food and Drug Administration for adjuvant treatment of patients with stage III melanoma after complete surgical resection. Despite this, clinicians and patients around the world and in many parts of the US have failed to embrace this treatment option because of the lack of overall survival benefit and minimal other clinical benefits seen in randomized trials, combined with the therapy's substantial toxicity. This article reviews the data from the randomized trials that lead to this conclusion and discuss why arguments often advanced in favor of using HD IFN are not persuasive. New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN.
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Authors: Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dreno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide
Journal: Clinical Cancer Research (2016)

To investigate changes of peripheral blood biomarkers and their impact on clinical outcome following treatment with ipilimumab in advanced melanoma patients.Changes in blood counts and the frequency of circulating immune cell populations analyzed by flow cytometry were investigated in 82 patients to compare baseline values with different time-points after starting ipilimumab. Endpoints were overall survival (OS) and best clinical response. Statistical calculations were done by Wilcoxon-matched pairs tests, Fisher exact test, Kaplan-Meier analysis, and Cox regression analysis.Increases in absolute lymphocyte counts (ALC) 2 to 8 weeks (P = 0.003) and in percentages of CD4+ and CD8+ T cells 8 to 14 weeks (P = 0.001 and P = 0.02) after the first dose of ipilimumab were correlated with improved survival. These associations did not meet significance criteria, when conservatively adjusted for multiple testing, but were additionally correlated with clinical responses (all P < 0.05). However, validation is required. Increases in all three factors were observed in 36% of patients, who had a favorable outcome and survival probabilities of 93.3% and 63.8% at 12 and 24 months, respectively. A partial or complete response was observed in 71% of these patients compared with only 8% in patients with decreases in ≥1 of the 3 factors, respectively. Changes of regulatory T cells or myeloid-derived suppressor cells were not associated with OS.Increases of ALC observed 2 to 8 weeks after initiation of ipilimumab and delayed increases in CD4+ and CD8+ T cells reflect changes associated with positive outcome. These changes represent surrogate marker candidates and warrant further validation. Clin Cancer Res; 22(19); 4848-58. ©2016 AACR.
P-180 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study
Authors: C. Vivaldi, C. Caparello, G. Pasquini, G. Musettini, S. Catanese, M. Lencioni, A. Falcone, E. Vasile
Journal: Annals of Oncology (2015)
Macromolecular Degradation Systems and Cardiovascular Aging
Authors: Hiroyuki Nakayama, Kazuhiko Nishida, Kinya Otsu
Journal: Circulation Research (2016)

Aging-related cardiovascular diseases are a rapidly increasing problem worldwide. Cardiac aging demonstrates progressive decline of diastolic dysfunction of ventricle and increase in ventricular and arterial stiffness accompanied by increased fibrosis stimulated by angiotensin II and proinflammatory cytokines. Reactive oxygen species and multiple signaling pathways on cellular senescence play major roles in the process. Aging is also associated with an alteration in steady state of macromolecular dynamics including a dysfunction of protein synthesis and degradation. Currently, impaired macromolecular degradation is considered to be closely related to enhanced inflammation and be involved in the process and mechanism of cardiac aging. Herein, we review the role and mechanisms of the degradation system of intracellular macromolecules in the process and pathophysiology of cardiovascular aging.
Effect of Food Supplements on Poorly Fed Workers
Authors: G. A. Smart, T. F. Macrae, P. A. Bastenie, P. E. Gregoire
Journal: BMJ (1948)

In a previous paper (Bastenie, Macrae, Smart, and Yudkin, 1945) the diet of the families of a group of employees at a works in Brussels was described in detail.In order to determine whether Ihe theoretical deficiencies which were found to exist had caused any marked deterioration the effects of the addition of a known supplement to the diet of these men have been investigated.This paper gives an account of the work.
Predictors of posttraumatic stress disorder after burn injury
Authors: S Perry, J Difede, G Musngi, A J Frances, L Jacobsberg
Journal: American Journal of Psychiatry (1992)

The authors' goal was to examine subjective and objective predictors of posttraumatic stress disorder (PTSD).Hospitalized burn patients were assessed 1 week after injury with both objective predictors (percent of burned area and facial disfigurement) and subjective predictors (emotional distress and perceived social support). The patients were then assessed 2, 6, and 12 months later for development of PTSD.Among 51 patients, 18 (35.3%) met PTSD criteria at 2 months. High rates of PTSD were also found at 6 months (N = 16, 40.0% of the 40 available patients) and 12 months (N = 14, 45.2% of the 31 available patients). PTSD was predicted by subjective variables assessed at baseline, but patients with more severe burns were not more likely to develop PTSD.The DSM-III-R diagnosis of PTSD relies on an objective evaluation of the stressor's severity. The prospective data in this study support those who argue that evaluations of the severity of the stressor might also take into account subjective factors.
PTU-028 The Internet: an alternative to postal consent
Authors: C Calvert, N Prasad, N Prasad
Journal: Gut (2010)

<h3>Introduction</h3> Valid informed consent is mandatory before endoscopy. This can be time consuming and is frequently inadequate. The process may be limited by time constraints, communication difficulties, the volume of information delivered, and patient apprehensions. Postal Consent has been advocated by the BSG but we present a feasible alternative. <h3>Methods</h3> Our website delivers detailed information regarding endoscopy and allows patients to consent online. The website systematically takes patients through the consent process with videos and images to illustrate the more complex concepts. Patients are given the opportunity to print and sign a consent form which they can bring to the endoscopy unit on the day of their procedure. <h3>Results</h3> Our own survey of 412 patients attending for endoscopy showed that 69% had Internet access and 83% felt that this website would be helpful. We found that 73% of patients were already using the Internet to obtain medical information and that 77% thought that the information they found was at least as good, if not better, than that received from health professionals. <h3>Conclusion</h3> A major benefit of online consent is that information can be interactive and multimedia enriched, which aids understanding. It will also allow patients the conveniences of time and location as well as improve efficiency in the endoscopy department.
Why the NHS should do more bariatric surgery; how much should we do?:
Authors: Richard Welbourn, Carel W le Roux, Amanda Owen-Smith, Sarah Wordsworth, Jane M Blazeby
Journal: BMJ (2016)

The number of people getting bariatric surgery is falling despite rising rates of obesity and diabetes. <b>Richard Welbourn and colleagues</b> examine why and argue that better access has potential to reduce long term costs of care
Drinking artificially sweetened drinks in pregnancy shows link to overweight infants
Authors: Jacqui Wise
Journal: BMJ (2016)

Pregnant women who drink artificially sweetened drinks every day during pregnancy are 100% more likely to have an infant who is overweight at age 1 than women who drink none,1 a study published in JAMA Pediatrics shows, although the researchers acknowledge that their study relies on self reported consumption of artificially sweetened drinks and cannot prove a causal association.

Meghan Azad and colleagues, from the University of Manitoba in Canada, studied 3030 women enrolled in the Canadian Infant Longitudinal …
Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups
Authors: Christian Thomas, Martin Sill, Vincent Ruland, Anika Witten, Stefan Hartung, Uwe Kordes, Astrid Jeibmann, Rudi Beschorner, Kathy Keyvani, Markus Bergmann, Michel Mittelbronn, Torsten Pietsch, Jörg Felsberg, Camelia M Monoranu, Pascale Varlet, Peter Hauser, Adriana Olar, Richard G Grundy, Johannes E Wolff, Andrey Korshunov, David T Jones, Melanie Bewerunge-Hudler, Volker Hovestadt, Andreas von Deimling, Stefan M Pfister, Werner Paulus, David Capper, Martin Hasselblatt
Journal: Neuro-Oncology (2016)

Choroid plexus tumors are intraventricular neoplasms derived from the choroid plexus epithelium. A better knowledge of molecular factors involved in choroid plexus tumor biology may aid in identifying patients at risk for recurrence. Methylation profiles were examined in 29 choroid plexus papillomas (CPPs, WHO grade I), 32 atypical choroid plexus papillomas (aCPPs, WHO grade II), and 31 choroid plexus carcinomas (CPCs, WHO grade III) by Illumina Infinium HumanMethylation450 Bead Chip Array. Unsupervised hierarchical clustering identified 3 subgroups: methylation cluster 1 (pediatric CPP and aCPP of mainly supratentorial location), methylation cluster 2 (adult CPP and aCPP of mainly infratentorial location), and methylation cluster 3 (pediatric CPP, aCPP, and CPC of supratentorial location). In methylation cluster 3, progression-free survival (PFS) accounted for a mean of 72 months (CI, 55-89 mo), whereas only 1 of 42 tumors of methylation clusters 1 and 2 progressed (P< .001). On stratification of outcome data according to WHO grade, all CPCs clustered within cluster 3 and were associated with shorter overall survival (mean, 105 mo [CI, 81-128 mo]) and PFS (mean, 55 mo [CI, 36-73 mo]). The aCPP of methylation cluster 3 also progressed frequently (mean, 69 mo [CI, 44-93 mo]), whereas no tumor progression was observed in aCPP of methylation clusters 1 and 2 (P< .05). Only 1 of 29 CPPs recurred. Methylation profiling of choroid plexus tumors reveals 3 distinct subgroups (ie, pediatric low-risk choroid plexus tumors [cluster 1], adult low-risk choroid plexus tumors [cluster 2], and pediatric high-risk choroid plexus tumors [cluster 3]) and may provide useful prognostic information in addition to histopathology.
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer—Reply
Authors: Dawn L. Hershman, Joseph M. Unger
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients
Authors: Robyn M. Scherber, Steven Knapper, Sonia Fox, Heidi E. Kosiorek, Marzia Shah, Sepehr Abdi-Moradi, Adam J Mead, Amylou C. Dueck, Samah Ailman, Anthony R Green, Marion Wood, Joanne Ewing, Fredrick Chen, Jason Coppell, Mary Frances McMullin, Holly Geyer, Ruben A. Mesa, Claire N. Harrison
Journal: Blood (2015)
Clinical significance of microRNAs in chronic and acute human leukemia
Authors: Chien-Hung Yeh, Ramona Moles, Christophe Nicot
Journal: Molecular Cancer (2016)

Small non-coding microRNAs (miRNAs) are epigenetic regulators that target specific cellular mRNA to modulate gene expression patterns and cellular signaling pathways. miRNAs are involved in a wide range of biological processes and are frequently deregulated in human cancers. Numerous miRNAs promote tumorigenesis and cancer progression by enhancing tumor growth, angiogenesis, invasion and immune evasion, while others have tumor suppressive effects (Hayes, et al., Trends Mol Med 20(8): 460–9, 2014; Stahlhut and Slack, Genome Med 5 (12): 111, 2013). The expression profile of cancer miRNAs can be used to predict patient prognosis and clinical response to treatment (Bouchie, Nat Biotechnol 31(7): 577, 2013). The majority of miRNAs are intracellular localized, however circulating miRNAs have been detected in various body fluids and represent new biomarkers of solid and hematologic cancers (Fabris and Calin, Mol Oncol 10(3):503–8, 2016; Allegra, et al., Int J Oncol 41(6): 1897–912, 2012). This review describes the clinical relevance of miRNAs, lncRNAs and snoRNAs in the diagnosis, prognosis and treatment response in patients with chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and acute adult T-cell leukemia (ATL).
Abstract 2051: Recombinant Factor VIIa Affects Vein Graft Patency and Flow in Rabbits
Authors: David Mazer, Howard Leong-Poi, Zuhair Alfardan, Zhilan Wang, Beiping Qiang, James Mahoney, David Latter, Bradley Strauss, Jerry Teitel
Journal: Circulation (2007)

INTRODUCTION: Recombinant factor VIIa (rVIIa) has been used to decrease postoperative bleeding in cardiac surgical patients. However, there is potential for rVIIa to interact with tissue factor expression at the site of new anastomoses resulting in early graft occlusion. This safety study tested the hypothesis that the administration of rVIIa dose-dependently reduces graft patency at the site of new vascular anastomoses comparable in size to human coronaries, in a rabbit model. METHODS: After ACC approval, a reversed venous graft was fashioned in the right carotid artery using autologous right jugular vein with 9 – 0 sutures in 64 anesthetized and heparinized rabbits. Animals were then given either one of three doses of rVIIa (300 ug/kg, 90 ug/kg or 20 ug/kg IV) or placebo (n=16/group). The primary outcome was graft patency, measured by a blinded observer 24 hours postoperatively using vascular ultrasound (HDI 5000cv, 15 MHz probe) and/or direct inspection. Factor VII activity levels were measured from citrated plasma samples with a 1-stage prothrombin time-based assay using rabbit thromboplastin. Data was analyzed using chi-square, fishers exact test, or ANOVA where appropriate, with p&lt;0.05 considered significant. RESULTS: Physiologic variables (ACT, hemoglobin, pH, pCO2) and vessel diameter were similar between groups. Graft patency and flow were significantly reduced, and plasma factor VII levels significantly increased in the rVIIa treated rabbits in a dose-dependent fashion. DISCUSSION: The study suggests that high doses of rVIIa (300 and 90 ug/kg) are associated with an increased incidence of occlusion of new vascular grafts. A clear dose-response effect was observed, suggesting that higher doses may be associated with increased thrombotic outcomes.